TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05808517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Tai Chi (TC) is a traditional Chinese exercise, also known as a mind-body exercise. It is suitable as an alternative or supplementary form of routine physical exercise for older adults. TC focuses on gentle and rhythmical movements while maintaining a meditative state. Low to moderate activities have benefits to improve sleep disturbances in older adults. In addition, growing evidence widely supports meditation as a potential intervention to improve sleep disturbances through reducing repetitive negative thoughts such as worry and rumination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: Tai Chi (TC) is a traditional Chinese exercise, also known as a mind-body exercise. It is suitable as an alternative or supplementary form of routine physical exercise for older adults. TC focuses on gentle and rhythmical movements while maintaining a meditative state. Low to moderate activities have benefits to improve sleep disturbances in older adults. In addition, growing evidence widely supports meditation as a potential intervention to improve sleep disturbances through reducing repetitive negative thoughts such as worry and rumination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: The brain stimulation technique repetitive transcranial magnetic stimulation (rTMS) provides the opportunity to non-invasively modulate cortical excitability. In general, low-frequency rTMS (≤ 1 Hz) is thought to inhibit cortical excitability.
Study: NCT05629507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The Virtual Reality intervention will administer through the use of a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo.~The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios).
Study: NCT05349383

Intervention type: DRUG
Intervention: Antibody-Drug Conjugate
Description: Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin.

Intervention type: DRUG
Intervention: Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
Description: We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
Study: NCT05852821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5STS remote assessment via videoconference
Description: Patients will be asked to perform several times the 5STS test, from their home through videoconference, on 3 occasions (day 1, 24h later and 1month later).
Study: NCT02001584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT05077007

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nephrolithotomy
Description: Endoscopic stone Extraction from the kidney by making a puncture and dilate a tract direct into the kidney through muscle wall and renal parenchyma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Lithotripsy
Description: Using Shock waves from outside the body targeted at a kidney stone causing the stone to fragment. The stones are broken into tiny pieces.
Study: NCT06097546

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test (RAI14 and MACC-1 )
Description: Measurement of serum RAI14 and serum MACC-1 levels by immunochemical assays

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test (RAI14 and MACC-1 )
Description: Measurement of serum RAI14 and serum MACC-1 levels by immunochemical assays

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test (RAI14 and MACC-1 )
Description: Measurement of serum RAI14 and serum MACC-1 levels by immunochemical assays
Study: NCT04617925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered as a monotherapy intravenously at a 2.5 mg/kg calculated dose
Study: NCT04948840

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
Study: NCT05778253

Intervention type: DIAGNOSTIC_TEST
Intervention: WES and ctDNA detection
Description: WES and ctDNA detection
Study: NCT06153706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subgingival application of L-PRF loaded with metronidazole
Description: After phase I therapy, L-PRF loaded medical grade metronidazole was applied sub gingivally into the pockets using blunt gauge needle and Perio-pack was placed (two applications with one week apart were applied subgingivally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival application of L-PRF
Description: The L-PRF alone was applied subgingivally into the pockets and Perio-pack was placed (two applications with one week apart.
Study: NCT05431322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Initially give loading dose with 0.5 mcg/kg for 10 min and then keep maintenance dose with 0.5 mcg/kg/h until two-lung ventilation.
Study: NCT05371899

Intervention type: DRUG
Group type: OTHER
Intervention: Chiauranib
Description: Take Chiauranib 50mg orally once daily
Study: NCT05507736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 13 Indwelling, sterile and disposable needles (SEIRIN NEW PYONEX® from 0.9 mm in length and 0.22 mm in diameter) on day 1 and 5 of the second cycle of irinotecan leaving them inserted for 4 days.
Study: NCT05167097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASSIST-linked Brief Intervention
Description: WHO's ASSIST-linked Brief Intervention (with and without Steps 6-9, the decisional balance element)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASSIST-linked Brief Intervention
Description: WHO's ASSIST-linked Brief Intervention (with and without Steps 6-9, the decisional balance element)

Intervention type: OTHER
Group type: OTHER
Intervention: Mindset Intervention
Description: Standard mindset manipulation as used in research by Peter M. Gollwitzer and colleagues

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindset Intervention
Description: Standard mindset manipulation as used in research by Peter M. Gollwitzer and colleagues

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindset Intervention
Description: Standard mindset manipulation as used in research by Peter M. Gollwitzer and colleagues
Study: NCT05093829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NmCV-5
Description: NmCV-5 is a pentavalent meningococcal (A, C, Y, W, X) polysaccharideconjugate vaccine composed of capsularpolysaccharides (PS) from Neisseria meningitidis serogroups A, C, Y, W, and X individually conjugated to a protein carrier, either mutant diphtheria toxoid (CRM197) or tetanus toxoid (TT).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NmCV-5
Description: NmCV-5 is a pentavalent meningococcal (A, C, Y, W, X) polysaccharideconjugate vaccine composed of capsularpolysaccharides (PS) from Neisseria meningitidis serogroups A, C, Y, W, and X individually conjugated to a protein carrier, either mutant diphtheria toxoid (CRM197) or tetanus toxoid (TT).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-TT
Description: MenACWY-TT (the comparator meningococcal vaccine) is a WHO-PQ quadrivalent meningococcal (A, C, Y, W) polysaccharide-conjugate vaccine manufactured by Pfizer.
Study: NCT06171074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection
Study: NCT05323370

Intervention type: OTHER
Intervention: 24h urine
Description: Urine samples will be collected at home over 24 hours

Intervention type: OTHER
Intervention: 24h urine
Description: Urine samples will be collected at home over 24 hours

Intervention type: OTHER
Intervention: 24h urine
Description: Urine samples will be collected at home over 24 hours

Intervention type: OTHER
Intervention: urine sample
Description: A urine sample of 20cc will be collected

Intervention type: OTHER
Intervention: urine sample
Description: A urine sample of 20cc will be collected
Study: NCT05093829

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-TT
Description: MenACWY-TT (the comparator meningococcal vaccine) is a WHO-PQ quadrivalent meningococcal (A, C, Y, W) polysaccharide-conjugate vaccine manufactured by Pfizer.
Study: NCT05088135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.
Description: It will be divided three groups as bilateral Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unilateral-Right Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.
Description: It will be divided three groups as unilateral-right Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unilateral-Left Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.
Description: It will be divided three groups as unilateral-left Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
Study: NCT05323370

Intervention type: OTHER
Intervention: urine sample
Description: A urine sample of 20cc will be collected
Study: NCT04901702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onivyde
Description: Given intravenous on Days 1 and 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onivyde
Description: Given intravenous on Days 1 and 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talazoparib
Description: Given orally twice on Day 1 (daily maximum is 1000mcg/day), then daily on Days 2-6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given once a day on Days 1-5.
Study: NCT05617417

Intervention type: OTHER
Group type: OTHER
Intervention: Local applied injectable platelet-rich fibrin in women with stress urinary incontinence
Description: Injectable platelet-rich fibrin was prepared by centrifuging venous blood taken from women with stress urinary incontinence and applied locally to the anterior vaginal wall of the patients.
Study: NCT04469504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation program
Description: 4-week trimodal prehabilitation program: Exercise, nutritional supplementation, and psychological support

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Impact
Description: perioperative immunonutrition by ORAL IMPACT
Study: NCT04518306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
Description: Oral tablets
Study: NCT06262009

Intervention type: OTHER
Intervention: human faecal collection
Description: collecting stools 6 times over a 90 days period and complete a questionnaire at the same times: D1, D7, D15, D30, D60 and D90

Intervention type: OTHER
Intervention: ancillary study
Description: interviews and/or ethnographic observations for 50 volunteers
Study: NCT05672225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.2mcg/kg/hr (2ml/hr) administration via continuous channel in the experimental group
Study: NCT04518306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
Description: Oral tablets
Study: NCT05672225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Normal saline 2ml/hr administration via continuous channel in the experimental group
Study: NCT06188299

Intervention type: OTHER
Group type: OTHER
Intervention: Restricted Fluid Administration
Description: Restrictive fluid administration generally consists of partial or no replacement for the intravascular expansion from anesthesia, in which case vasopressors are usually administered, no replacement for the third space loss, and only partial replacement for deficits from preoperative fasting.
Study: NCT05423912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple in Control (CiC) Program
Description: MCI dyads engaging in the pilot testing aim of the CiC Program meet in virtual intervention group meetings lasting 90 to 120 minutes over the course of 8-9 consecutive weeks. Participants are asked to take part in structured quantitative interviews at baseline and 4 and 8 weeks post-intervention. A subsample of participants will be interviewed virtually via videoconference for a 30 to 60 minute discussion on their experiences in and perceptions of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple in Control (CiC) Program
Description: MCI dyads engaging in the pilot testing aim of the CiC Program meet in virtual intervention group meetings lasting 90 to 120 minutes over the course of 8-9 consecutive weeks. Participants are asked to take part in structured quantitative interviews at baseline and 4 and 8 weeks post-intervention. A subsample of participants will be interviewed virtually via videoconference for a 30 to 60 minute discussion on their experiences in and perceptions of the intervention.
Study: NCT04518306

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04768660

Intervention type: OTHER
Group type: OTHER
Intervention: gum
Description: Other: Chewing gum ChiczaTM organic chewing gum 6 pieces a day Other: Glucose 12ml glucose solution (13,6g) per day
Study: NCT04639011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Three doses of 60 mg of oral duloxetine will be given to participants (right before operation, postop day 1, postop day 2)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Three doses of placebo will be given to participants (right before operation, postop day 1, postop day 2).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC) for tibial plateau surgery
Description: Postoperative IV administration of opioids via a patient controlled analgesia (PCA) system which utilizes a hydromorphone pump.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC) for tibial plateau surgery
Description: Postoperative IV administration of opioids via a patient controlled analgesia (PCA) system which utilizes a hydromorphone pump.
Study: NCT05720468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Combined endurance and resistance exercise training
Study: NCT04709328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTA01
Description: Diluted by 0.9% normal saline，IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTA01
Description: Diluted by 0.9% normal saline，IV
Study: NCT05720468

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Exercise
Description: Continue usual level of physical activity; option to participate in exercise training program after 26-week intervention period
Study: NCT06233149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole magnesium dihydrate-Test product
Description: Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
Study: NCT05015686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd
Description: live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
Study: NCT06233149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole magnesium dihydrate-Reference product
Description: Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
Study: NCT06221748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Injection
Description: Phase II and III study ：2.5mg/kg, intravenous infusion，D1, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Injection
Description: Phase II and III study ：2.5mg/kg, intravenous infusion，D1, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab Injection
Description: Phase II and III study ：6.0mg/kg, intravenous infusion，D1, every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Injection
Description: Phase II and III study ：Calculate dosage based on body surface are,160mg/m2,intravenous infusion，D1,D8 every 3 weeks
Study: NCT06175169

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Information of Appendix (IA) model
Description: Deep learning model
Study: NCT05173961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use oncpatient mobile application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT05756569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05512013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Description: Ibuprofen taken orally 2 hours prior to exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg
Description: Celebrex taken orally 2 hours prior to exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Description: Flurbiprofen taken orally 2 hours prior to exercise
Study: NCT04709328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTA01
Description: Diluted by 0.9% normal saline，IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study: NCT05512013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert placebo taken orally 2 hours prior to exercise
Study: NCT05756569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05123755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AV-001 Injection
Description: AV-001 (mpaBr) Cl for Injection 2.5 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AV-001 Placebo Injection
Description: D-PBS
Study: NCT06352307

Intervention type: OTHER
Intervention: Diagnosis of ACM
Description: Definite ACM diagnosis is based on the consensus-based 2010 Task Force Criteria, which include major and minor criteria in six categories (depolarization and repolarization abnormalities, arrhythmia, imaging, histology, and family history/genetics). Among these, repolarization abnormalities (T-wave inversion in the precordial leads) constitute the most commonly observed, followed by frequent premature ventricular complex. With regards to imaging techniques, both the presence of wall motion abnormalities and an abnormal ventricular volume or function are required for fulfilment. Definite ACM consists of two major criteria or one major and two minor criteria or four minor criteria from different categories. Borderline ACM consists of one major and one minor criterion or three minor criteria from different categories.

Intervention type: OTHER
Intervention: Diagnosis of ACM
Description: Definite ACM diagnosis is based on the consensus-based 2010 Task Force Criteria, which include major and minor criteria in six categories (depolarization and repolarization abnormalities, arrhythmia, imaging, histology, and family history/genetics). Among these, repolarization abnormalities (T-wave inversion in the precordial leads) constitute the most commonly observed, followed by frequent premature ventricular complex. With regards to imaging techniques, both the presence of wall motion abnormalities and an abnormal ventricular volume or function are required for fulfilment. Definite ACM consists of two major criteria or one major and two minor criteria or four minor criteria from different categories. Borderline ACM consists of one major and one minor criterion or three minor criteria from different categories.

Intervention type: OTHER
Intervention: Diagnosis of ACM
Description: Definite ACM diagnosis is based on the consensus-based 2010 Task Force Criteria, which include major and minor criteria in six categories (depolarization and repolarization abnormalities, arrhythmia, imaging, histology, and family history/genetics). Among these, repolarization abnormalities (T-wave inversion in the precordial leads) constitute the most commonly observed, followed by frequent premature ventricular complex. With regards to imaging techniques, both the presence of wall motion abnormalities and an abnormal ventricular volume or function are required for fulfilment. Definite ACM consists of two major criteria or one major and two minor criteria or four minor criteria from different categories. Borderline ACM consists of one major and one minor criterion or three minor criteria from different categories.